AMR Stakeholder Profile
Focus area/active in: Therapeutics
Company/Organisation type: SME
Polyphor is a research based clinical stage biopharmaceutical company, targeting first in class molecules, focused in oncology and antimicrobial resistance. Polyphor has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria and constitutes potentially a major breakthrough in the fight against antimicrobial resistance.The research and preclinical programs focuses on three targets; LptD/E: Inhaled Murepavadin (POL7080), LPS and BamA: POL7306 and LptA: Thanatin.
Get in touch!
Please fill out the form below to get in touch with us.